Anti-Ebolavirus GP/Glycoprotein Reference Antibody (Larcaviximab, RUO)
- Catalog number: BS10520
- Availability: In Stock
$176.00
- Ex Tax: $176.00
Description: Larcaviximab (BS10520) is a research-grade recombinant antibody targeting Envelope glycoprotein. Produced in mammalian cells with native-like glycosylation.
Highlights:
• Research Grade — For PK/PD studies, assay development, and ADA research.
• Native Glycosylation — Mammalian expression ensures native-like patterns.
Host species: Chimeric
Isotype: IgG1,kappa
Species reactivity: Zaireebolavirus(ZEBOV)
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.01M PBS, pH7.4.
Concentration: 1mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: Research Grade Biosimilar
Target: Envelopeglycoprotein,GP1,2,GP,ShedGP,GP1,2-delta,GP1,GP2,GP
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names: c4G7-N,CAS:1792982-56-9
Background: Envelope glycoprotein (GP) is a ~74 kDa protein. Trimeric GP1,2 complexes form the virion surface spikes and mediate the viral entry processes, with GP1 acting as the receptor-binding subunit and GP2 as the membrane fusion subunit. At later times of infection, down-regulates the expression of various host cell surface molecules that are essential for immune surveillance and cell adhesion. Down-modulates several integrins including ITGA1, ITGA2, ITGA3, ITGA4, ITGA5, ITGA6, ITGAV and ITGB1. This decrease in cell adhesion molecules may lead to cell detachment, contributing to the disruption of blood vessel integrity and hemorrhages developed during infection (cytotoxicity) (Probable). Interacts with host TLR4 and thereby stimulates the differentiation and activation of monocytes leading to bystander death of T-lymphocytes.
References:
1. Simmons, G. et al. (2002) Journal of virology 76, 2518-28. PMID: 1183643
2. Takada, A. et al. (2000) Virology 278, 20-6. PMID: 11112476
3. Iampietro, M. et al. (2017) PLoS pathogens 13, e1006397. PMID: 28542576
4. Edri, A. et al. (2018) Frontiers in immunology 9, 1428. PMID: 30013549
5. Vande Burgt, NH. et al. (2015) Viruses 7, 5587-602. PMID: 2651690
6. Brinkmann, C. et al. (2016) Journal of virology 90, 11075-11086. PMID: 27707924
7. González-Hernández, M. et al. (2018) Journal of virology 92. PMID: 29669839
8. Rizk, MG. et al. (2017) Journal of virology 91. PMID: 28878074
Note: For research use only. Not suitable for clinical or therapeutic use.
Highlights:
• Research Grade — For PK/PD studies, assay development, and ADA research.
• Native Glycosylation — Mammalian expression ensures native-like patterns.
Host species: Chimeric
Isotype: IgG1,kappa
Species reactivity: Zaireebolavirus(ZEBOV)
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.01M PBS, pH7.4.
Concentration: 1mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: Research Grade Biosimilar
Target: Envelopeglycoprotein,GP1,2,GP,ShedGP,GP1,2-delta,GP1,GP2,GP
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names: c4G7-N,CAS:1792982-56-9
Background: Envelope glycoprotein (GP) is a ~74 kDa protein. Trimeric GP1,2 complexes form the virion surface spikes and mediate the viral entry processes, with GP1 acting as the receptor-binding subunit and GP2 as the membrane fusion subunit. At later times of infection, down-regulates the expression of various host cell surface molecules that are essential for immune surveillance and cell adhesion. Down-modulates several integrins including ITGA1, ITGA2, ITGA3, ITGA4, ITGA5, ITGA6, ITGAV and ITGB1. This decrease in cell adhesion molecules may lead to cell detachment, contributing to the disruption of blood vessel integrity and hemorrhages developed during infection (cytotoxicity) (Probable). Interacts with host TLR4 and thereby stimulates the differentiation and activation of monocytes leading to bystander death of T-lymphocytes.
References:
1. Simmons, G. et al. (2002) Journal of virology 76, 2518-28. PMID: 1183643
2. Takada, A. et al. (2000) Virology 278, 20-6. PMID: 11112476
3. Iampietro, M. et al. (2017) PLoS pathogens 13, e1006397. PMID: 28542576
4. Edri, A. et al. (2018) Frontiers in immunology 9, 1428. PMID: 30013549
5. Vande Burgt, NH. et al. (2015) Viruses 7, 5587-602. PMID: 2651690
6. Brinkmann, C. et al. (2016) Journal of virology 90, 11075-11086. PMID: 27707924
7. González-Hernández, M. et al. (2018) Journal of virology 92. PMID: 29669839
8. Rizk, MG. et al. (2017) Journal of virology 91. PMID: 28878074
Note: For research use only. Not suitable for clinical or therapeutic use.
Images
-
BioactivitySEC-HPLC detection for Research Grade Larcaviximab.
-
SDS-PAGESDS-PAGE for Research Grade Larcaviximab.
